Showing 20 of 49 recruiting trials for “extranodal-nasal-nkt-cell-lymphoma”
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
👨⚕️ Gottfried von Keudell, MD, PhD, Beth Israel Deaconess Medical Center📍 1 site📅 Started Feb 2026View details ↗
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
👨⚕️ Shuhua yi, Hematology Hospital, Chinese Academy of Medical Sciences📍 14 sites📅 Started Jan 2026View details ↗
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
RecruitingNCT06712459 ↗
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
👨⚕️ Luca Arcaini, MD, Fondazione IRCCS Policlinico San Matteo📍 7 sites📅 Started Oct 2025View details ↗
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Aug 2025View details ↗
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2025View details ↗
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
👨⚕️ Fei Li, professor, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Dec 2024View details ↗
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Oct 2024View details ↗
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Enrolling by InvitationNCT07450040 ↗
Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
Page 1 of 3Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →